Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 5.9 -4.07% -0.25
AQST closed down 4.07 percent on Wednesday, April 24, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 8

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical AQST trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -4.07%
Inside Day Range Contraction -4.07%
20 DMA Resistance Bearish -5.30%
Bollinger Band Squeeze Range Contraction -5.30%
20 DMA Resistance Bearish -6.20%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.20%

Older signals for AQST ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Amyotrophic Lateral Sclerosis Epilepsy Chloroarenes Psychoactive Drugs Opioids Gabaa Receptor Positive Allosteric Modulators Lactams Parkinson’s Disease Neuroendocrine Tumors Riluzole
Is AQST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.7
52 Week Low 5.6
Average Volume 107,091
200-Day Moving Average 0.0
50-Day Moving Average 6.7056
20-Day Moving Average 6.3735
10-Day Moving Average 6.159
Average True Range 0.4339
ADX 13.82
+DI 14.2022
-DI 21.1083
Chandelier Exit (Long, 3 ATRs ) 5.7983
Chandelier Exit (Short, 3 ATRs ) 7.1617
Upper Bollinger Band 6.9884
Lower Bollinger Band 5.7586
Percent B (%b) 0.11
BandWidth 19.295521
MACD Line -0.1924
MACD Signal Line -0.1746
MACD Histogram -0.0178
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.40
Resistance 3 (R3) 6.44 6.31 6.31
Resistance 2 (R2) 6.31 6.19 6.29 6.28
Resistance 1 (R1) 6.11 6.11 6.05 6.07 6.26
Pivot Point 5.98 5.98 5.95 5.96 5.98
Support 1 (S1) 5.78 5.86 5.72 5.74 5.54
Support 2 (S2) 5.65 5.78 5.63 5.52
Support 3 (S3) 5.45 5.65 5.49
Support 4 (S4) 5.41